DataM Intelligence Projects In-Silico Clinical Trials Market to Reach $6.39 Billion by 2033
The in-silico clinical trials market is projected to reach USD 6.39 billion by 2033, up from USD 3.95 billion in 2024, expanding at a compound annual growth rate of 5.5% between 2025 and 2033, announced in a press release by DataM Intelligence.
In-silico trials use computational modeling, virtual patient simulations, and AI-driven predictive systems to digitally test drug candidates, medical devices, and treatment protocols. These digital simulations complement laboratory and clinical studies by improving prediction accuracy and reducing experimental workloads.
The report highlights that pharmaceutical companies, medical device manufacturers, contract research organizations, and academic institutions are increasingly adopting in-silico trial platforms to modernize clinical development. The approach helps address challenges such as high development costs, regulatory delays, and patient recruitment difficulties, ultimately shortening the time to market for new therapies.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Adsilico Raises £10 Million for Virtual Medical Device Testing
Isomorphic Labs Seeks $5 Billion at $50 Billion Valuation
Boehringer Ingelheim and Microsoft to Study Digital Patient Twins
Causal AI Market Forecast to Reach $761.4 Million by 2031
Inovia Bio Launches Falcon for Drug Development Workflows
Daily AI Brief: the AI news that matters, in your inbox.